Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624
This examiner grants 85% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18426461 | Novel Heteroaryl Aminopropanol Derivatives | Non-Final OA | NOVARTIS AG |
| 18546087 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | Non-Final OA | Hoffmann-La Roche Inc. |
| 18554265 | (S)-3-AMINO-4-(DIFLUOROMETHYLENE)CYCLOHEXENE AND CYCLOHEXANE CARBOXYLIC ACID AND USES THEREOF AS SELECTIVE INACTIVATORS OF HUMAN ORNITHINE AMINOTRANSFERASE (hOAT) | Non-Final OA | Northwestern University |
| 18555213 | SPIRO-COMPOUNDS AND COMPOSITIONS INCLUDING THE SAME | Final Rejection | Solventum Intellectual Properties Company |
| 18576535 | INDAZOLE YL BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Non-Final OA | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS |
| 17793204 | MULTICYCLIC CARBOCATION AND CARBORADICAL COMPOUNDS AND METHODS OF USE | Non-Final OA | Arizona Board of Regents on Behalf of the University of Arizona |
| 18443829 | SPIROCYCLIC COMPOUNDS | Non-Final OA | ASTRAZENECA AB |
| 18019771 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18335325 | Acesulfame Potassium Compositions and Processes for Producing Same | Final Rejection | Celanese International Corporation |
| 18335296 | Acesulfame Potassium Compositions and Processes for Producing Same | Final Rejection | Celanese International Corporation |
| 18335285 | Acesulfame Potassium Compositions and Processes for Producing Same | Final Rejection | Celanese International Corporation |
| 18335345 | Acesulfame Potassium Compositions and Processes for Producing Same | Final Rejection | Celanese International Corporation |
| 18580545 | IONIC SCINTILLATORS | Non-Final OA | UNIVERSITÉ DE STRASBOURG |
| 18263702 | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES | Non-Final OA | MEDSHINE DISCOVERY INC. |
| 17597868 | Method for Preparing Key Intermediate of ABT-737 and Method for Preparing ABT-737 | Non-Final OA | Xeon Biopharmaceutical Limited |
| 18517894 | SALTS OF A PI3Kdelta INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE | Non-Final OA | BeiGene Switzerland GmbH |
| 18566048 | NOVEL OXAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALLERGIC DISEASES COMPRISING THE SAME | Non-Final OA | AZCURIS CO., LTD. |
| 18223443 | CITRATE SALT, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | FOGHORN THERAPEUTICS INC. |
| 18504848 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | Non-Final OA | EMPATHBIO, INC. |
| 18556746 | COMPOSITION FOR PREVENTING OR TREATING DISEASES CAUSED BY MITOCHONDRIAL DYSFUNCTION, CONTAINING ISOQUINOLINE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | Non-Final OA | ALTMEDICALCO., LTD. |
| 18554426 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | Non-Final OA | SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. |
| 18282940 | PRODRUGS OF KV7 CHANNEL OPENERS | Non-Final OA | Xyzagen, Inc. |
| 18282943 | PRODRUGS OF KV7 CHANNEL OPENERS | Non-Final OA | Xyzagen, Inc. |
| 18282934 | PRODRUGS OF KV7 CHANNEL OPENERS | Non-Final OA | Xyzagen, Inc. |
| 18278246 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF STRESS-RELATED DISORDERS | Non-Final OA | NIPPON CHEMIPHAR CO., LTD. |
| 18278234 | Polycyclic Compound for Inhibiting RNA Helicase DHX33, and Application of Compound | Non-Final OA | Shenzhen KeYe Life Technologies, Co., Ltd |
| 18278192 | A PROPYL PROPANE THIOSULFONATE COMPOUND FOR USE AS ANTITUMORAL | Final Rejection | DMC RESEARCH CENTER, SL |
| 18263870 | FUSED TRICYCLIC CYCLIN-DEPENDENT KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Non-Final OA | Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
| 18262941 | NEW MOLECULAR SCAFFOLD FOR TARGETING HRPN13 | Non-Final OA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE |
| 18253916 | SMALL MOLECULE INHIBITOR FOR CATHEPSIN C AND MEDICINAL USE THEREOF | Non-Final OA | REISTONE BIOPHARMA COMPANY LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy